New DMTC project bringing medical and industrial expertise together

DMTC Limited has announced the commencement of a new project under Round Three of its Medical Countermeasures Program. The project will advance the development of a new Australian antibiotic by partnering its developer, Boulos & Cooper Pharmaceuticals, with manufacturing experts from CSIRO.

Early stage trials have shown the drug Ramizol® – developed by Perth-based company Boulos & Cooper – to be effective against Clostridium difficile infection (or CDI), an increasingly common hospital-acquired infection in both military field hospital and public health settings.

Boulos & Cooper has demonstrated that Ramizol® is particularly active against Gram-positive bacteria, and is also chemically stable in a variety of conditions, reducing storage and transportation costs and increasing its potential to be safely and rapidly deployed to remote locations.

As a key partner in the DMTC team, experts at CSIRO Manufacturing will trial innovative continuous-flow processing techniques to create the desired compound and also to demonstrate the capacity to scale up the manufacturing process in future.

Full Media Release (PDF)

Posted by Harry Baxter on December 4th, 2018 Tagged: , , , , , , ,